salt-wasting (SW) and simple-virilizing (SV) types, which are associated with the severity of impaired 21-hydroxylase activity.
The gene that encodes 21-hydroxylase, CYP21A2, is known to be located at the HLA class III region of the short arm of chromosome 6 (6p21.3). 3 Most mutations that involve the CYP21A2 are either large gene deletions 4, 5 or transfer of deleterious sequences from the pseudogene CYP21A1P to the active gene CYP21A2, in a process termed gene conversion. [6] [7] [8] [9] The diagnosis of 21-OHD is based on the clinical presentation and laboratory tests, including the adrenocorticotropin (ACTH) stimulation test. 10, 11 A newborn screening program has been implemented in Taiwan since 2007 to prevent morbidity and mortality, by testing blood spot 17-hydroxyprogesterone (17-OHP) levels. 12, 13 However, false-negative neonatal screening results in severely affected patients with 21-OHD are still observed. 14 This study analyzed the initial clinical and laboratory features of Taiwanese children with 21-OHD in the pre-screening era, to arouse physicians' index of suspicion for diagnosing this disorder. It also aimed to provide background information for the ongoing neonatal screening program for 21-OHD in Taiwan.
Patients and Methods

Subjects
Eighty patients diagnosed with classic CAH caused by 21-OHD, from 1977 to 2006, but not detected by neonatal screening at the Department of Pediatrics, National Taiwan University Hospital were enrolled. Their medical records were reviewed throughly. The diagnosis of 21-OHD was based on clinical evidence of androgen excess, glucocorticoid and/or mineralocorticoid deficiency, with elevated basal and/or ACTH-stimulated 17-OHP levels. Patients with serum sodium levels < 135 mmol/L and/or serum potassium levels > 5.5 mmol/L were classified as SW-type 21-OHD.
Complete physical examination and assessment of external genitalia were carried out in all patients with 21-OHD upon diagnosis. Laboratory tests, including serum levels of sodium, potassium, chloride, basal ACTH, cortisol, 17-OHP, dehydroepiandrosterone sulfate (DHEAS), androstenedione, and testosterone, as well as blood gas analysis were also checked upon diagnosis. All of the blood samples were obtained before the initiation of hormone replacement therapy. The 60-minute ACTH stimulation test was performed in 22 patients to confirm the diagnosis of 21-OHD as previously reported. 11 All serum hormone levels were assayed by commercially available kits. Bone age was determined in patients aged > 3 years and was evaluated according to Greulich and Pyle's criteria. 15 Karyotyping and pelvic sonography were performed in girls who presented with ambiguous genitalia.
Molecular analysis
After diagnosis of 21-OHD, 62 patients (including 11 siblings from 5 families) underwent genotyping of the CYP21A2 gene in peripheral blood leukocytes. Both parents were also genotyped to confirm the origin of the mutations. All of the subjects provided informed consent. The eight most common mutation sites from exons 1 to 8 were analyzed initially by allele-specific polymerase chain reaction (PCR), as described previously. 16 When none of the eight point mutations or deletions could account for a diseased allele, direct single strand conformation polymorphism (SSCP) analysis was done. Primary PCR was performed to amplify specifically the full-length of CYP21A2, as previously described. 17 Ten sets of primers were designed to perform secondary PCR using the primary PCR products as templates to amplify 10 exons. The secondary PCR products were subjected to SSCP analysis using a GenePhor Unit (Pharmacia Biotech, Uppsala, Sweden). The uncharacterized band of exon 9 on the SSCP gel was cut and the DNA was extracted and re-amplified with the same SSCP primers. 
Statistical analysis
Data were expressed as median and range, and analyzed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). The Mann-Whitney U test was used for between-group comparison. A p value < 0.05 was considered statistically significant.
Results
Demographic data
Of the 80 21-OHD patients, 11 were siblings from five families. None of the 80 patients had a family history of consanguinity. Thirty-nine (21 boys and 18 girls) patients had SW-type and 41 (10 boys and 31 girls) had SV-type 21-OHD. As shown in Table 1 , boys with SW-type 21-OHD detected by the parents was significantly younger than those with SVtype (8 days vs. 4.5 years; p < 0.01). The situation was similar for girls. However, boys were detected at a later age than girls for both SW-and SV-type 21-OHD. The median age of diagnosis for SWtype 21-OHD was also significantly younger than that for SV-type (p < 0.01). However, the median age of diagnosis did not differ significantly between boys and girls for either SW-or SV-type 21-OHD.
Clinical manifestations
The clinical manifestations of 21-OHD patients are shown in Table 2 . The most frequent initial clinical 
Laboratory findings
As shown in Table 3 Serum DHEAS and androstenedione levels were measured in 28 and 29 patients, respectively. The median value was 4.9 μmol/L (range, 0.8-66.5 μmol/L) for DHEAS and 43.9 nmol/L (range, 19.9-2820 nmol/L) for androstenedione. Twenty-two patients had elevated serum DHEAS levels, and all had serum androstenedione levels above the normal range as suggested by Tung et al. 18 Serum testosterone was measured in 47 patients. The median value was 14.6 nmol/L (range, 1.7-293.0 nmol/L). All of these values were above the normal range for the age group concerned. There were statistically significant differences between SW-and SV-type 21-OHD for serum androstenedione and testosterone levels ( Table 3) . Serum electrolyte levels were measured in 32 patients with SW-type 21-OHD. Thirty-one had hyponatremia and 29 had hyperkalemia at the time of diagnosis, and four had seizures caused by hyponatremia. Among patients with SW-type 21-OHD, 14/16 (88%) boys had a serum sodium level below 125 nmol/L, and 8/16 (50%) girls had a serum sodium level below 125 nmol/ L (p < 0.05). Seventeen patients with SW-type 
Molecular diagnosis
The results of molecular analysis of 57 patients from different families are shown in Table 4 . Overall, mutations were detected in 94% of the chromosomes examined. The most frequent mutations detected were I172N (22.8%), mutation at IVS2-12A/C G (21.1%), and gene deletion (14%). Among these, IVS2-12A/C G (24.1%) and gene deletion (24.1%) were detected most frequently in patients with SW-type 21-OHD, whereas Il72N (46.4%) and IVS2-12A/C G (17.9%) were detected most frequently in patients with SV-type 21-OHD. One novel mutation at exon 9 was identified in a patient with SV-type 21-OHD. This involved a deletion from codons 396 to 400 of exon 9, with a segment from intron 6 (nucleotides 1520-1560) inserted at codon 396. This mutation caused a stop codon at 15 codons downstream from the insertion site.
Among the 50 patients with mutations detected on both chromosomes, four each were homozygotes for gene deletion, large gene conversion, or IVS2-12A/C G. All four patients had SW-type 21-OHD. Three homozygotes that carried the mutation Il72N had SV-type 21-OHD. One patient with compound heterozygosity for IVS2-12A/C G in trans with R356W was SVtype. Twenty-four patients who were compound heterozygotes with any combination of gene deletion, large gene conversion, IVS2-12A/C G, c.707-714del, a cluster of mutations at exon 6, stop mutation, or R356W had SW-type 21-OHD. On the other hand, 18 patients who were compound heterozygotes for I172N mutations in trans with any of the above-mentioned mutations had SV-type 21-OHD.
Discussion
CAH is a group of autosomal recessive disorders that are caused most frequently by 21-OHD. 2, 19, 20 Classic CAH caused by 21-OHD can be further divided into SW-and SV-types according to the severity of impaired 21-hydroxylase activity. In the present study, the number of SW-and SV-type patients was similar. The proportion of SW-type patients in our study was less than that expected based on previous studies [21] [22] [23] [24] or our newborn screening program. 13 Such discrepancy suggests that a greater proportion of SW-type 21-OHD patients in the pre-screening era could have died from adrenal crisis without a definite diagnosis, because of the nonspecific presentation in boys with SW-type 21-OHD or their parents' and doctors' lack of knowledge of this disorder. Excess androgen production affects the external genitalia of girls with CAH, therefore, the clinical manifestations in girls are more obvious than those in boys with CAH. The age at diagnosis was not significantly different between boys and girls in the present study, which is different from previous reports. 21, 22, 24 It also reflects a lack of alertness of parents and doctors in diagnosing CAH in the pre-screening era in Taiwan, even with obvious findings on the external genitalia of girls with CAH. Although CAH caused by 21-OHD impairs glucocorticoid synthesis, most of the patients in our study had low, normal basal serum cortisol levels upon diagnosis. However, such levels are not adequate for patients in the presence of stress and elevated ACTH levels. Conversely, serum basal 17-OHP levels were elevated in all of these patients. These results demonstrated that serum 17-OHP levels are more reliable than plasma ACTH or cortisol levels for diagnosing 21-OHD in children.
In terms of serum androgen levels, 79% of patients had serum DHEAS above the normal range for their age, whereas all patients had serum androstenedione and testosterone levels above the normal range for their age. There was no statistically significant difference in serum DHEAS levels in patients with SW-and SV-type 21-OHD. However, the serum levels of androstenedione and testosterone in SW-type patients were significantly higher than those of SV-type patients (p < 0.01). Although serum DHEAS level is specific for adrenal androgen production, the data here showed that serum androstenedione and testosterone levels are more sensitive in diagnosing 21-OHD than is serum DHEAS level, which confirms our previous findings. 25 In this study, the distinction between SW-and SV-type 21-OHD was based on serum electrolyte levels. It is well known that plasma renin activity and aldosterone levels are more precise in reflecting the activity of the renin-angiotensinaldosterone system, and patients with SW-type 21-OHD have high renin activity and low plasma aldosterone levels. 26 A large proportion of the patients in the present study were diagnosed before the availability of assays, therefore, such data were not presented in this study. However, the determination of plasma renin activity or direct renin level is recommended for the diagnosis of CAH. 27 The most frequent mutations in our patients were I172N, IVS2-12A/C G and gene deletion, which were similar to those previously reported. 17, 28 Among these, IVS2-12A/C G and gene deletion were the most common mutations in SW-type 21-OHD, and I172N and IVS2-12A/ C G were the most common in SV-type. It has been reported previously that the most frequent mutations are deletion and large gene conversion in SW-type 21-OHD, IVS2-12A/C G in SW-and SV-types, and I172N in SV-type. 19, 20 The effect of CYP21A2 mutations on the enzymatic activity of 21-hydroxylase is well documented. 4, [6] [7] [8] 19, 20, 29 The results here confirmed the correlation between specific mutations and phenotypes reported previously. 19, 20 All patients with homozygous mutations for CYP21A2 reflected the severity of impaired 21-hydroxylase activity. The phenotype of our patients with compound heterozygosity for two different CYP21A2 mutations was often compatible with that of the less severe gene defects. 19, 20, 30 Furthermore, most of our patients who were heterozygous for IVS2-12A/C G with a more severe gene defect had SW-type 21-OHD, but a minority of patients with this mutation had SVtype. The possibility that intronic mutations such as IVS2-12A/C G alternatively activate cryptic splice acceptor sites, with the production of some normally processed mRNA, could explain why patients with SV-type 21-OHD carry IVS2-12A/ C G. 6, 19, 20, 29, 30 On the other hand, one patient who was a compound heterozygote for P30L and large gene conversion (P30L, IVS2-12A/C G, c.707-714del, I172N) had SV-type 21-OHD. Although the P30L enzyme activity has been reported to be impaired mildly in vitro, the SV clinical phenotype has been reported in patients who are compound heterozygotes for P30L and a severe mutation. 31, 32 The P30L mutation as part of a larger gene deletion/conversion event with a junction site before intron 2 has been proposed to account for such a finding. 32 In conclusion, the present study demonstrates the clinical findings of Taiwanese children with CAH caused by 21-OHD, as well as a good correlation between genotype and phenotype in these patients. Although clinical findings are more obvious in girls, the diagnosis of 21-OHD is delayed in both boys and girls. This study could help physicians to recognize this disease entity. With improved knowledge of parents and physicians, and with the help of the neonatal screening program for 21-OHD, such a delay in diagnosis can hopefully be avoided in Taiwan in the near future.
